Last updated on July 2019

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hemophilia A
  • Age: - 100 Years
  • Gender: Male

Inclusion Criteria:

  • Male patients diagnosed with moderate to severe hemophilia A ( 5% FVIII:C (Factor VIII Coagulant activity))
  • Any age
  • 50 exposure days (EDs) to any FVIII product
  • Patients with or without history of inhibitors
  • Patient with previous history of inhibitors, with at least 2 consecutive negative inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to study entry
  • No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor
  • Evidence of FVIII inhibitor as measured by the Nijmegen-modified Bethesda assay[<0.6 Bethesda units (BU/mL)] or Bethesda assay [< 1.0 BU/mL] in 2 on consecutives samples
  • Documented or clinical suspicion of shortened FVIII half-life (< 6 hrs)
  • Currently on or plan to start prophylaxis therapy with KOVALTRY
  • Written informed consent

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice
  • Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A
  • Patients on Immune Tolerance Induction (ITI) treatment at the time of enrollment

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.